NASDAQ · SLN
Healthcare · Biotechnology
$13.53
Up+$1.21 (+8.94%)
Updated Sep 2, 2026, 12:10 AM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SLN closed at $13.53 after 20 trading sessions, up 21.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $13.39 | $13.6499 | $13.0896 | $13.53 | 476.83K |
| Aug 28, 2026 | $13.46 | $13.685 | $13.18 | $13.42 | 539.7K |
| Aug 27, 2026 | $13.47 | $13.685 | $13.36 | $13.45 | 283.67K |
| Aug 26, 2026 | $13.68 | $13.68 | $13.355 | $13.53 | 301.7K |
| Aug 25, 2026 | $13.31 | $13.99 | $13.31 | $13.67 | 645.03K |
| Aug 24, 2026 | $13.37 | $13.59 | $13.05 | $13.29 | 723.69K |
| Aug 21, 2026 | $13.17 | $13.48 | $13.13 | $13.27 | 740.55K |
| Aug 20, 2026 | $13.50 | $13.5699 | $13.01 | $13.17 | 585.26K |
| Aug 19, 2026 | $14.59 | $14.59 | $13.47 | $13.61 | 977.26K |
| Aug 18, 2026 | $14.17 | $14.355 | $13.67 | $14.10 | 1.49M |
| Aug 17, 2026 | $13.75 | $14.41 | $13.55 | $14.35 | 1M |
| Aug 14, 2026 | $14.01 | $14.2197 | $13.44 | $13.72 | 824.06K |
| Aug 13, 2026 | $14.07 | $14.24 | $13.36 | $13.97 | 2.81M |
| Aug 12, 2026 | $14.75 | $15.24 | $13.55 | $13.58 | 5.44M |
| Aug 11, 2026 | $15.97 | $16.5234 | $14.6301 | $14.72 | 3.29M |
| Aug 10, 2026 | $16.70 | $17.5758 | $14.62 | $15.43 | 16.21M |
| Aug 7, 2026 | $11.96 | $12.305 | $11.74 | $11.95 | 316.89K |
| Aug 6, 2026 | $11.27 | $11.8229 | $11.27 | $11.72 | 252.8K |
| Aug 5, 2026 | $11.07 | $11.45 | $10.86 | $11.24 | 452.23K |
| Aug 4, 2026 | $10.98 | $11.48 | $10.78 | $11.17 | 518.64K |
The latest Smart Investors Daily articles mentioning SLN.
SLN research
Company profile and research snapshot.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $25 to $32.
SeekingAlpha · Aug 11, 2026
2026-08-11. The following slide deck was published by Silence Therapeutics plc in conjunction with this event.
SeekingAlpha · Aug 10, 2026
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera August 10, 2026 8:00 AM EDTCompany...
Benzinga · Aug 10, 2026
Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLN.
